https://www.selleckchem.com/pr....oducts/vx803-m4344.h
Whether AR-V7 expression can predict the response in patients with metastatic hormone-sensitive prostate cancer (mHSPC) who receive androgen deprivation therapy (ADT) remains to be explored. To evaluate the predictive value of AR-V7 expression in the prognosis of mHSPC patients receiving ADT. In this multicenter prospective cohort study, 310 mHSPC patients commencing ADT were enrolled. Standard immunohistochemical staining was used to assess AR-V7 protein expression in biopsy tissues collected before initiation of ADT. Kaplan-Meier
Like
Comment
Share
